Chiroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chiroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mike head who wrote (28)	6/23/1998 6:58:00 PM
From: Elayne Shochet Tatar	Read Replies (1) of 69

Testing news from Chiroscience today in Wall Street Journal: Dow Jones Newswires -- June 23, 1998 Chiroscience: D2163 Showed Anti-Tumor Activity In Rats Dow Jones Newswires LONDON -- Chiroscience Group PLC said its D2163 matrix metalloprotease, or MMP, development compound showed strong anti-tumor activity when administered orally to mice or rats bearing experimental tumors. In a press release Tuesday, Chiroscience said that further development of D2163, including a repeat-dose study in normal subjects, and phase I, II and III studies in cancer patients, will be conducted by Bristol-Myers Squibb Co. (BMY). The company said D2163 is an inhibitor of MMP-2 and of angiogenesis. Chiroscience is a pharmaceutical company. Copyright c 1998 Dow Jones & Company, Inc. All Rights Reserved.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next